Cargando…
HGG-32. UNCOVERING THERAPEUTIC VULNERABILITIES IN MISMATCH REPAIR-DEFICIENT GLIOMAS
INTRODUCTION: We have observed that approximately 26% of recurrent gliomas acquire hypermutation following treatment with temozolomide (TMZ). Intriguingly, 91% of these tumors harbor mutations in mismatch repair (MMR) genes. Strategies to target MMR-deficient gliomas thus stand to impact a large num...
Autores principales: | Boynton, Adam, Pal, Sangita, Touat, Mehdi, Currimjee, Naomi, Qian, Kenin, Bellamy, Charlotte, Ho, Patricia, Berstler, Jim, Ligon, Keith, Beroukhim, Rameen, Bandopadhayay, Pratiti |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715373/ http://dx.doi.org/10.1093/neuonc/noaa222.314 |
Ejemplares similares
-
HGG-51. Uncovering therapeutic vulnerabilities in mismatch repair-deficient gliomas
por: Boynton, Adam, et al.
Publicado: (2022) -
HGG-41. STRUCTURAL VARIANT DRIVERS IN PEDIATRIC HIGH-GRADE GLIOMA
por: Dubois, Frank, et al.
Publicado: (2020) -
HGG-52. SUSTAINED RESPONSE TO CRIZOTINIB MONOTHERAPY IN AN INFANT WITH GOPC-ROS1 FUSED CONGENITAL HEMISPHERIC GLIOMA
por: Lulla, Rishi, et al.
Publicado: (2020) -
HGG-44. DEFECTS OF MISMATCH REPAIR PROTEINS IN PEDIATRIC HIGH GRADE GLIOMAS
por: Haberler, Christine, et al.
Publicado: (2020) -
HGG-44. REVEALING VULNERABILITIES IN DIPG THROUGH ONC201
por: Stafford, James, et al.
Publicado: (2021)